Intervention Review

You have free access to this content

Haloperidol versus placebo for schizophrenia

  1. Clive E Adams1,*,
  2. Hanna Bergman2,
  3. Claire B Irving1,
  4. Stephen Lawrie3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 15 NOV 2013

Assessed as up-to-date: 15 MAY 2012

DOI: 10.1002/14651858.CD003082.pub3


How to Cite

Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD003082. DOI: 10.1002/14651858.CD003082.pub3.

Author Information

  1. 1

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  2. 2

    Enhance Reviews Ltd, Wantage, UK

  3. 3

    University of Edinburgh, Department of Psychiatry, Edinburgh, Scotland, UK

*Clive E Adams, Cochrane Schizophrenia Group, The University of Nottingham, Institute of Mental Health, University of Nottingham Innovation Park, Triumph Road,, Nottingham, NG7 2TU, UK. clive.adams@nottingham.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 15 NOV 2013

SEARCH

  1. You have free access to this content

    Current Version

    Haloperidol versus placebo for schizophrenia

    Clive E Adams, Hanna Bergman, Claire B Irving and Stephen Lawrie

    Article first published online: 15 NOV 2013 | DOI: 10.1002/14651858.CD003082.pub3

Previous versions of this article and their online publication dates

  1. Version 2

    Haloperidol versus placebo for schizophrenia

    Claire B Irving, Clive E Adams and Stephen Lawrie

    Article first published online: 18 OCT 2006 | DOI: 10.1002/14651858.CD003082.pub2

  2. Version 1

    Haloperidol versus placebo for schizophrenia

    CB Joy, CE Adams and SM Lawrie

    Article first published online: 23 APR 2001 | DOI: 10.1002/14651858.CD003082